Shimrit Harlev-Ringelstein

Haifa, HA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Journal: Transplantation and cellular therapy

Published: April 24, 2026

Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.

Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.

Journal: European journal of haematology

Published: November 19, 2025

Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma.

Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma.

Journal: Haematologica

Published: November 02, 2025

Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell Lymphoma.

Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: September 03, 2025

Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: September 03, 2025

Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Journal: Blood advances

Published: July 15, 2025

Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.

Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.

Journal: Blood advances

Published: July 15, 2025

Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm.

Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm.

Journal: British journal of haematology

Published: January 26, 2025

CCR5 predicts neurotoxicity in CAR-T-cell therapy.

CCR5 predicts neurotoxicity in CAR-T-cell therapy.

Journal: British journal of haematology

Published: January 22, 2025

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.

Journal: Haematologica

Published: October 08, 2024

In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab.

In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab.

Journal: Annals of hematology

Published: August 01, 2024

Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma.

Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma.

Journal: Journal of clinical medicine

Published: July 13, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026